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ABSTRACT Repeated' tr~atment with the non-selective dopamine agonist apoJior-
phine results in behavioral sensitization and enhanced dopamine synthesis in dopantlne 
projection fields. To examine the role ofD2-type dopamine receptors in modulating these 
effects, the present experiment assessed the effects of repeated treatment with lthe 
D2-type agonist quinpirole on locomotor activity and dopamine synthesis. In the first 
experiment, rats were treated with vehicle or one of two doses (0.3 or 3.0 mg/k~) of 
quinpirole for 8 days. Daily measures oflocomotor activity revealed an initial suppression 
of activity produced by quinpirole which dissipated over the 8 days of treatment. A trl.nd 
for an increase in activity for 3.0 mg/kg quinpirole compared to vehicle was obtained on 
day 8. Twenty-four hours after cessation of treatment, dopamine synthesis, measured as 
accumulation of 3,4-dibydroxyphenylalanine (DOPA) after treatment with the DOPA 
decarboxylase inhibitor NSD-1015, was enhanced in the striatum, but not nucleus\ ac-
cumbens-olfactory tubercle (NAOT) or ventral mesencephalon (VM). In Experiment 2, 
rats were treated for 8 days with vehicle, 3.0 mg/kg quinpirole or the D1 antagonist ~CH 
23390 (0.5 mg/kg) in a two (vehicle or quinpirole) x two (vehicle or SCH 23390) desjgn. 
Quinpirole-alone treatment resulted in a reduction of the locomotor suppressant effects 
of the drug. SCH 23390-alone and quinpirole-SCH 23390 combined treatment resultei! in 
decreased activity compared to the vehicle control group that did not cliange across dhs. 
DOPA accumulation was enhanced in the striatum and NAOT after quinpirole tr~at­
ment; however, SCH 23390 had no effect. In Experiment 3, rats were treated for 10 days 
with vehicle, 3.0 mg/kg quinpirole or the D2 antagonist eticlopride (LO mg/kg) in a two 
(vehicle or quinpirole) X two (vehicle or eticlopride) design. As in the first two exp:eri-
ments, repeated quinpirole-alone treatment resulted in a redµction of the locomotor 
suppressant effects of the drug; however, locomotor activity in this group was enhariced 
compared to vehicle controls on day 10. Eticlopride-alone and eticlopride-quinpitole 
treated rats had suppressed locomotor activity across the 10 days. DOPA accumulation 
was enhanced by both repeated quinpirole and repeated eticlopride treatment in jthe 
striatum and NAOT. DOPA accumulation in eticlopride-quinpirole treated rats was 
1
not 
different from vehicle control levels in the NAOT, while no significant difference was 
obtained between the eticlopride-alone and eticlopride-quinpirole groups in the striat\im. 
The locomotor activity data suggest that repeated quinpirole treatment results in toler-
ance to the locomotor suppressant effect of the drug. Evidence for sensitization fvas 
obtained in two out of three of the experiments. These results suggest that enhanced 
dopamine synthesis after repeated non-selective dopamine agonist treatment is mtidu-. ' lated by D2-type dopamme receptors. © 1995 Wiley-Liss, Inc. 
INTRODUCTION 
Drugs that act as direct or indirect agonists for 
dopamine receptors often produce a progressive en-
hancement of the acute behavioral effects of the drugs 
following repeated treatment. This phenomenon is 
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Fig. 1. Activity counts (mean ± SEM) per 20-min session across the 
8 days of treatment with quinpirole or vehicle (n = 13 rats/group). 
and quinpirole versus vehicle treatment. The within-
subjects factors were day or brain regions. Violations of 
homogeneity of variance were examined using the 
Huyn-Feldt epsilon. Degrees of freedom were corrected 
if the epsilon value was < 0. 75. Multiple comparisons 
were made using the Dunnett's test comparing drug 
groups to the vehicle control or Student's t-tests. For 
the ANOV As and multiple comparisons, the alpha level 




The locomotor activity data for the 8 days ofrepeated 
quinpirole treatment are shown in Figure 1. As may be 
seen, both doses of quinpirole produced a significant 
inhibition of locomotor activity on the first treatment 
day. This inhibitory effect of quinpirole, however, de-
clined with repeated treatments. As expected, a nrixed 
factorial ANOVA revealed a significant main effect of 
day, F(7,252) = 8.84, P < 0.0001, and a significant 
drug dose x day interaction, F(14,252) = 10.23, 
P < 0.0001. To further examine the effect of repeated 
quinpirole treatment on locomotor activity, an ANOVA 
was performed on the day 8 data. This analysis re-
vealed a significant effect of drug dose, F(2,36) = 4.20, 
P < 0.05; however, Dunnett's tests did not reveal sig-
nificant differences of the two doses compared to the 
vehicle controls. These results are consistent with those 
observed previously in this laboratory using the same 
procedure (Mattingly et al., 1993). 
DOPA accumulation 
The DOPA accumulation results of Experiment 1 are 
shown in Figure 2. A mixed factorial ANO VA revealed a 
significant main effect of region, F(2, 72) = 209.9, 
P < 0.0001 and a significant region x quinpirole dose 
interaction, F(4,72) = 3.06, P < 0.05. Multiple compar-
isons revealed that DOPA levels in the striatum were 
significantly elevated at both doses of quinpirole com-
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Fig. 2. DOPA accumulation (mean percent of vehicle control in µg/ 
g ± percent SEM for each group) for rats treated 8 days with quinpi-
role or vehicle (n = 13/group). All rats were treated with NSD-1015 
(100 mg/kg) on day 9 prior to dissection of the striatum, NAOT (nu-
cleus accumbens-olfactory tubercle) and VM (ventral mesencephalon). 
Note that"*" indicates a significant difference from control (Dwmett's 
tests, P < 0.05). 
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Fig. 3. Activity counts (mean ± SEM) per 20-min session across the 
8 days of treatment with combinations of quinpirole (QUIN, 3.0 mg/ 
kg), SCH 23390 (SCH, 0.5 mg/kg) or vehicle (VEH; n ~ 12 rats/group). 
Experiment 2 
Locomotor activity 
The locomotor activity data for the 8 days ofrepeated 
quinpirole-SCH 23390 treatment are shown in Figure 
3. As may be seen in this figure, SCH 23390 treatment 
significantly suppressed locomotor activity and pre-
vented the progressive increase in quinpirole-induced 
locomotor activity. A mixed factorial ANOVA revealed 
the following significant between-subjects effects: quin-
pirole main effect, F(l,44) = 15.22, P < 0.001; SCH 
23390 main effect, F(l,44) = 272.27, P < 0.0001; 
quinpirole x SCH 23390 interaction, F(l,44) = 22.65, 
P < 0.0001. The following effects involving repeated mea-
sures were significant: day main effect, F(7,308) = 13. 77, 
P < 0.0001; quinpirole x day interaction, F(7,308) = 
25.87, P < 0.0001; SCH 23390 x day interaction, 
F(7,308) = 10.69, P < 0.0001; quinpirole x SCH 23390 
x day interaction, F(7,308) = 17.68, P < 0.0001. The 
significant overall interaction likely reflects the grad-
' 
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Fig. 4. DOPA accumulation (mean percent-of vehicle control in µg/ 
g ± percent SEM for each group) for rats treated 8 days with combina-
tions of quinpirole (QUIN, 3.0 mg/kg), SCH 23390 (SCH, 0.5 mg/kg) or 
vehicle (VEH; n = 12/group). All rats were treated with NSD-1015 
(100 mWk:g) on day 9 prior to dissection of the striatum, NAOT (nu-
cleus accumbens-olfacto:ry tubercle) and VM (ventral mesencephalon). 
Note that"*" indicates a significant difference from control (Dunnett's 
test,P < 0.05). 
ual increase to control levels by rats treated with vehi-
cle and quinpirole, while all other groups did not 
change across days. An ANOVA performed on day 8 
revealed a significant main effect of SCH 23390, 
F(l,44) = 194.42, P < 0.0001. The main effect of quin-
pirole treatment approached, but did not achieved sig-
nificance, F(l,44) = 3.77, P = 0.0586. Tbe interaction 
of quinpirole and SCH 23390 and all multiple compari-
sons on day 8 were not significant. These findings also 
are consistent with our previous study (Mattingly et al., 
1993). 
DOPA accumulation 
Tbe DOPA accumulation results for the three brain 
regions are shown in Figure 4. A mixed factorial 
ANOVA revealed significant main effects of quinpirole 
treatment, F(l,44) = 14.08, P < 0.001, and region, 
F(2,88) = 385.41, P < 0.0001 (epsilon = 0.62). The in-
teraction ofregion x quinpirole treatment also was sig-
nificant, F(2,88) = 12.32, P < 0.001 (epsilon= 0.62). 
No main effect or interaction involving SCH 23390 
treatment was significant, suggesting that SCH 23390 
co-treatment was without effect on DOPA accumula-
tion. Indeed, multiple comparisons revealed that DOPA 
levels in the vehicle-quinpirole and SCH 23390-quinpi-
role treated rats were significantly greater than control 
in both striatumand NAOT (Dunnett's tests, P < 0.05). 
Comparisons of DOPA levels in striatum and NAOT of 
the vehicle-quinpirole and SCH 23390-quinpirole rats 
revealed no significant difference (Student's t-test, 
p > 0.05). 
Experiment 3 
Locomotor activity 
Tbe locomotor activity data for the 10 days of re-
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Fig. 5. Activity counts (mean± SEM) per 2()..min session across 
the 10 days of treatment with combinations of qUinpirole (QUIN, 3.0 
mg/kg), eticlopride (ETIC, 1.0 mg/kg) or vehicle](VEH; n = 12 rats/ 
group). . : 
' Figure 5. Like SCH 23390 treatment, eticlopride treat-
ment inhibited locomotor activity and blocked the pro-
gressive increase in quinpirole-induce~ locomotor ac-
tivity. A mixed factorial ANOVA revealed a significant 
between-subjects main effect of eticlopride, F(l,44) = 
98.55, p < 0.0001, only. Tbe following effects involving 
repeated measures were significant: day main effect, 
F(9,396) = 4.95, P < 0.0001; quinpirolJ x day interac-
' tion, F(9,396) = 13.36, P < 0.0001; eticlopride x day 
interaction, F(9,396) = 3.35, P < O.OOl; quinpirole x 
eticlopride x day interaction, F(9,39G) = 5.25, P < 
0.0001. An ANOVA performed on day 10 revealed a 
significant main effect of quinpirole,' F(l,44) = 7.77, 
P < 0.01, and of eticlopride, F(l,44) = 41.48, P < 
0.0001. The interaction of quinpirole and SCH 23390 on 
day 10 was not significant. Dunnett's tests showed that 
the group treated with quinpirole and vehicle had sig-
nificantly greater locomotor activity counts than the 
vehicle control group (P < 0.05). Thus~ after 10 daily 
treatments, quinpirole significantly increased locomo-
tor activity relative to vehicle control rats. In addition, 
both groups treated with eticlopride ~hawed signifi-
cantly lower locomotor activity couhts than the controls 
(P < 0.05). ' 
DOPA accumulation 
The DOPA accumulation results for ,the three brain 
regions are shown in Figure 6. A mixed factorial 
ANOVA revealed a significant main ~!feet of region, 
F(2,86) = 87.72, P < 0.0001 (epsilon =i0.68). No other 
main effects or interactions were significant. The inter-
action of quinpirole treatment and eticlopride treat-
ment approached, but did not achie~e significance, 
F(l,46) = 3.85,P = 0.056.AsinExperii\ient2, multiple 
comparisons showed that DOPA accumhlation was sig-
nificantly increased in vehicle-quinpirble treated rats 1 
compared to controls iu both the striatum and NAOT 
(Dunnett's tests, P < 0.05). Compariso!is between con-
trols and the eticlopride-quinpirole tl-eated rats re-
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Fig. 6. DOPA accumulation (mean percent of vehicle control in µ.gl 
g ± percent SEM for each group) for rats treated 10 days with combi-
nations of quinpirole (Q, 3.0 mg/kg), eticlopride (E, 1.0 mg/kg) or vehi-
cle (n = 12/group). All rats were treated with NSD-1015 (100 mg/kg) 
on day 11 prior to dissection of the striatum, NAOT (nucleus accum-
bens-olfactory tubercle) and VM (ventral mesencephalon). Note that 
"*" indicates a significant difference from control (Dunnett's test, 
p < 0.05). 
vealed a significant increase in DOPA accumulation for 
the striatum, but not NAOT (Dunnett's tests, P < 0.05). 
However, DOPA levels also were elevated in the eticlo-
pride-vehicle treated rats compared to controls in both 
striatum and NAOT (Dunnett's tests, P < 0.05). Addi-
tional t-tests comparing eticlopride-vehicle and eticlo-
pride-quinpirole rats revealed no significant differ-
ences. 
DISCUSSION 
Consistent with our previous findings, acute quinpi-
role treatment resulted in dose-dependent suppression 
of locomotor activity (Mattingly et al., 1993). With re-
peated treatment, the locomotor suppressant effect of 
quinpirole diminished until the activity levels of quin-
pirole-treated rats were equal to (Experiments 1 and 2), 
or greater than (Experiment 3), vehicle-treated rats. 
This progressive increase in quinpirole-induced loco-
motor activity is consistent with our previous work 
(Mattingly et al., 1993). Within the present paradigm, 
whether this increase in quinpirole-induced activity 
should be interpreted as tolerance or sensitization is 
unclear. However, previous work in other laboratories 
using longer test intervals has demonstrated a biphasic 
inhibitory-excitatory effect of quinpirole following a 
single administration and a clear sensitization effect 
with repeated administration (Eilam et al., 1992). Sim-
ilarly, the direct D2-type dopamine receptor agmrist 
bromocryptine also depressed locomotor activity when 
first presented, but resulted in locomotor sensitization 
with repeated treatment (Hoffinan and Wise, 1992). 
Thus, the lack of a clear sensitization effect in the 
present study may be related to the relatively short 
duration of the activity test used. 
The major finding of the present experiment was that 
repeated quinpirole treatment resulted in enhanced 
DOPA accumulation in the striatum and NAOT. Thus, 
consistent with previous studies with repeated apomor-
phine treatment (Rowlett et al., 1991, 1993; Vaughn et 
al., 1990), repeated stimulation of D2-type dopamine 
receptors resulted in enhanced dopamine synthesis in 
dopamine terminal fields. We have previously noted 
that enhanced dopamine synthesis in the NAOT follow-
ing repeated apomorphine treatment may be a rela-
tively weak effect compared to the effect obtained in the 
striatum (Rowlett et al., 1993). Some evidence for a 
similar relationship between dopamine synthesis in the 
NAOT and striatum following repeated quinpirole was 
obtained in the present series of experiments. Thus, 
while striatal dopamine synthesis was clearly in-
creased in all three experiments, the enhanced dopa-
mine synthesis effect was obtained in the NAOT only in 
Experiments 2 and 3, but not Experiment 1. Moreover, 
the magnitude of the percentage increase in DOPA ac-
cumulation in the NAOT varied from experiment to 
experiment, whereas the magnitude of the percentage 
increase in DOPA accumulation in the striatum was 
relatively consistent across experiments. The reason 
for this difference in DOPA accumulation results be-
tween the striatum and NAOT is not clear; however, 
the results may reflect a differential modulation of 
dopamine synthesis between the striatum and NAOT. 
Experiment 2 demonstrated that co-administration 
of the selective D1 receptor antagonist SCH 23390 did 
not block the enhanced dopamine synthesis effect pro-
duced by repeated quinpirole treatment. This finding is 
consistent with modulation of dopamine synthesis by 
D2 autoreceptors, and not D1-type receptors (Brown et 
al., 1985; Wachtel et al., 1989; White and Wang, 1984b; 
Wolf and Roth, 1990). Further, this finding is consis-
tent with a previous study which indicated that D1 re-
ceptor stimulation does not result in enhanced dopa-
mine synthesis (Rowlett et al., 1993). The results of 
Experiment 3 suggest that the D2-type antagonist eti-
clopride blocked the enhanced dopanrine synthesis ef-
fect produced by quinpirole in the NAOT. This finding 
is consistent with eticlopride's high selectivity for D2-
type receptors and provides further evidence for D2-
type modulation of the enhanced dopamine synthesis 
effect. In the striatum, there was no significant differ-
ence in DOPA accumulation between the eticlopride-
vehicle and eticlopride-quinpirole treated rats, also 
suggestive ofa blockade of the enhanced dopamine syn-
thesis effect produced by repeated quinpirole treat-
ment. However, dopamine synthesis was enhanced fol-
lowing repeated eticlopride treatment in both striatum 
and NAOT. This finding was unexpected and the rea-
son for this enhanced dopamine synthesis effect follow-
ing repeated eticlopride treatment is not clear. One pos-
sibility is that eticlopride was present in the brain at 
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notion comes from previous findings that acute eticlo-
pride treatment produces enhanced DOPA accumula-
tion (Tyler and Galloway, 1992) and Dz-type antago-
nists produce enhanced dopamine neuron impulse flow 
(White and Wang, 1984b). Irideed, O'Dell et al. (1993) 
reported that repeated eticlopride treatment (four in-
jections at 2-h intervals) resulted in enhanced striatal 
dopamine release, measured with in vivo microdialysis. 
It is also possible, however, that repeated eticlopride 
treatment resulted in some neurochemical alteration 
that indirectly enhanced dopamine synthesis. For ex-
ample, repeated eticlopride treatment results in up-
regulation of Dz-type receptors (LaHoste and Marshall, 
1991); however, up-regulation of autoreceptors would 
likely result in decreased dopamine synthesis. These 
issues clearly require further investigation; neverthe-
less, evidence for a blockade of repeated quinpirole-
induced enhanced dopamine synthesis in the NAOT 
clearly was obtained, in spite of the increase in DOPA 
accumulation produced by repeated eticlopride alone. 
The observation of an enhanced dopamine synthesis 
effect after repeated quinpirole treatment is consistent 
with the notion that repeated non-selective dopamine 
agonist treatment produces a reduction in dopamine 
autoreceptor sensitivity (e.g., Henry et al., 1989; Jezior-
ski and White 1989; Rebec and Lee, 1982; Rowlett et al., 
1991, 1993; White and Wang, 1984a). Indeed, the re-
sults of this study combined with our previous findings 
indicate that the enhanced dopamine synthesis effect 
observed after repeated apomorphine treatment likely 
is modulated by Dz-type autoreceptors. Taken together, 
our findings are consistent with an hypothesis for the 
development of behavioral sensitization advanced by 
Henry et al. (1989). Specifically, these authors sug-
gested that repeated cocaine treatment results in sub-
sensitivity of impulse-regulating autoreceptors fol-
lowed by terminal field D1 receptor supersensitivity. 
The results of the present study and our previous study 
(Mattingly et al., 1993) showing cross-sensitization of 
quinpirole and apomorphine that was blocked by a D1 
antagonist are consistent with this hypothesis. Thus, 
repeated quinpirole treatment may result in autorecep-
tor subsensitivity, which in turn results in enhanced 
dopamine release and consequent D1 stimulation. In 
the present study, blockade of D1 receptors had no ef-
fect on dopamine synthesis after repeated quinpirole 
treatment. Therefore, autoreceptor subsensitivity may 
occur without the development oflocomotor sensitiza-
tion. 
Recent molecular biological studies have identified at 
least five subtypes of dopamine receptors (see Schwartz 
et al., 1993). Of these subtypes, quinpirole binds with 
higher affinity to the D3 subtype than to the D2 or D 4 
subtypes, whereas apomorphine is relatively non-selec-
tive for the Dz subtypes (Levesque et al., 1992; Sokoloff 
et al., 1990; Van Toi et al., 1991). Based upon this affin-
ity difference, it may be speculated that the enhanced 
I 
dopanrine synthesis effect observed ~fter repeated 
quinpirole and apomorphine treatment may involve re-
peated D3 · receptor stimulation. However, it is not 
known if the doses used in the present study differenti-
ate between the two subtypes. In addition, the most 
robust augmentation of dopamine synth~sis occurred in 
the striatum, an area that has low levels of D3 mRNA, 
as well as low binding levels of the D3 !ii;'and [3H]7-0H-
DPAT (Levesque et al., 1992; Schwartz et al., 1993; 
Sokoloff et al., 1990). Thus, the role of D3 versus D2 
receptors in the ellhanced dopamine sJ,nthesis effect 
remains to be determined. I 
Finally, another possible mechanisiJi of enhanced 
dopamine synthesis following repeated apomorphine 
treatment involves an alteration of tyrpsine hydroxy-
Iase activity. Apomorphine, in addition to having 
dopamine receptor binding properties, also may be car-
ried into dopamine neurons where it inhibits tyrosine 
hydroxylase activity directly at the pt~ridine cofactor 
site (Laschinski et al., 1984). Based on tHe results of the 
present study, however, this effect of ap~morphine may 
not be involved in the enhanced dopaicine synthesis 
effect because quinpirole does not have alcatechol struc-
ture (Titus et al., 1983). Thus, any changes in tyrosine 
hydroxylase activity following repeated Dz agonist 
treatment are likely due to an indirect iJ\fluence on the 
enzyme rather than direct drug-induced!changes at the 
pteridine cofactor site. 1 
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